The aim of the HTA programme is to ensure that high quality research information on the effectiveness, costs and broader impact of health technologies is produced in the most efficient way for those who use, manage, provide care in or develop policy for the NHS. Topics for research are identified and prioritised to meet the needs of the NHS. Health technology assessment forms a substantial portfolio of work within the National Institute for Health Research and each year about fifty new studies are commissioned to help answer questions of direct importance to the NHS. The studies include both primary research and evidence synthesis. Question In which groups of diabetic patients can screening intervals for diabetic retinopathy be safely extended 1 Intervention: Screening strategies for diabetic retinopathy. 2 Patient group: Patients with Type 1 and Type 2 diabetes attending Diabetic Eye Screening Services. 3 Setting: Diabetic eye screening services in England. In general, as the programme in Scotland differs from that in England, proposals should not include delivery in Scotland, but may include Wales and Northern Ireland where similar. 4 Control or comparator treatment: Annual retinopathy screening as undertaken in England. 5 Design: Primary research using routinely collected clinical data to model the clinical and cost-effectiveness of different screening intervals, informed by the development of an algorithm to identify those patients in whom eye screening may be safely extended. A wide range of risk markers should be explored such as: type of diabetes; age; ethnicity; duration since onset; blood pressure; HbA1C; microalbuminurea; and grade of retinopathy. 6 Important outcomes: A risk-based algorithm for screening interval; cost-effectiveness; adverse events. Other outcomes: Key recommendations for further research. Background to commissioning brief: The UK has implemented a diabetic retinopathy screening programme. Timplementation in the different countries of the UK. Retinopathy means damage to the capillaries at the back of the eye, called the retina. Raised blood glucose levels caue microvascular damage throughout the body. In the eye, some small retinal blood vessels close off and others dilate, leading to two types of disease: Diabetic Macular Oedema (DMO) and Diabetic Retinopathy (DR). Damage to these vessels causes haemorrhages, which can seriously affect vision. After 20 years of diabetes, nearly all patients with Type 1 diabetes and over 60% of patients with Type 2 diabetes have some degree of retinopathy. Untreated diabetic retinopathy is the most common cause of blindness in working age people in the UK. NICE guidelines for diabetic patients recommend eye screening at, or around, the time of diagnosis and repeated examination by annual surveillance. For many patients, however, annual screening may be unnecessarily frequent, increasing costs to the NHS and inconvenience to patients. Scottish Guidelines published in March 2010 note screening intervals may be extended to two years for those with no signs of retinopathy.
CPV
73110000, 73210000, 85140000
The full text of tenders is available for registered users only.
Business opportunities: Unrestricted use in just 3 steps!
Sign in, select a tender category and get full trial access to tenders.
Test 15 Days Free
Benefits:
No more missed opportunities. Email alerts leave you time to focus on the bid. Profit from the most comprehensive tender database in Europe. An individually adapted search profile that will deliver only suitable tenders. A choice of subscription suitable for the size and needs of you company.
How it works in 3 easy steps:
Register for a FREE 15-day trial and experience the full service. Select a predefined search profile or create an individual one. Get business opportunities by email, daily.
No more missed opportunities. Email alerts leave you time to focus on the bid.
Back to search list
RSS